Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer

NCT01671319 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT01671319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01671319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
April 30, 2013
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

female breast cancer